Revolution Medicines
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Revolution Medicines generated cash of -$350,572,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,229,200,000 last year. Net change in cash is therefore $536,030,000.
Cash Flow
| 2017 | -25.14M | -1.57M | 22.66M |
|---|---|---|---|
| 2018 | 1.21M | -1.33M | 60.84M |
| 2019 | -49.61M | -101.96M | 98.65M |
| 2020 | -100.06M | -234.23M | 422.77M |
| 2021 | -147.18M | -142.11M | 294.17M |
| 2022 | -224.40M | -24.11M | 301.43M |
| 2023 | -350.57M | -342.59M | 1.22B |
RVMD Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 163.14M | 110.23M | 105.35M | 16.87M | 69.8M | 9.07M | 13.14M |
Operating activities | |||||||
Net income | -436.36M | -248.70M | -187.09M | -108.15M | -47.66M | -41.78M | -31.12M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 9.30M | 9.65M | 7.33M | 6.54M | 3.34M | 1.76M | 1.18M |
Stock-based compensation expense | 61.77M | 31.19M | 20.72M | 8.88M | 3.16M | 0 | 141K |
| Deferred income tax benefit | 61.77M | 31.19M | 20.72M | 8.88M | 3.16M | 0 | 141K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 3.41M | 1.25M | 464K | 2.34M | -1.43M | 0 | 0 |
Inventories | 0 | 0 | 7.68M | -2.34M | 1.43M | 0 | 0 |
Accounts payable | 32.46M | 7.28M | 2.23M | 305K | 5.26M | 109K | 1.96M |
Cash generated by operating activities | -350.57M | -224.40M | -147.18M | -100.06M | -49.61M | 1.21M | -25.14M |
Investing activities | |||||||
Purchases Of Investments | -1.05B | -612.76M | -671.33M | -544.13M | -172.26M | 0 | 0 |
Investments In Property Plant And Equipment | -7.72M | -10.81M | -6.52M | -2.93M | -2.58M | -1.49M | -1.57M |
Acquisitions Net | 0 | 13.3M | 135.58M | 231.3M | 196K | 160K | 0 |
Cash generated by investing activities | -342.59M | -24.11M | -142.11M | -234.23M | -101.96M | -1.33M | -1.57M |
Financing activities | |||||||
Common Stock Issued | 385.75M | 298.04M | 291.24M | 420.06M | 100.02M | 420K | 74K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 3.31M | 0 | 1.87M | 832K | -45K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.22B | 301.43M | 294.17M | 422.77M | 98.65M | 60.84M | 22.66M |
Net Change In Cash | 536.03M | 52.91M | 4.88M | 88.47M | -52.92M | 60.72M | -4.06M |
Cash at end of period | 699.17M | 163.14M | 110.23M | 105.35M | 16.87M | 69.8M | 9.07M |
| Data source | Data source | Data source | Data source | Data source |